iRxReminder, LLC, a pioneer in medical adherence technology, is thrilled to announce the enrollment of its first patients in the innovative NIMH-funded study, the TDtect Diagnostic. The study leverages iRxReminder’s cutting-edge Internet of Things (IoT) monitoring technology and technology partner Videra’s advanced machine-learning capabilities to validate automated identification of Tardive Dyskinesia, a potentially life-threatening adverse event associated with certain medications used by mental health patients. The TDtect study is a collaborative multi-center research effort, with initial patients enrolled at the esteemed Charak Research Center in Cleveland, OH, and Fermata.Health in New York, NY. This marks a pivotal moment in automating medication monitoring with IoT hardware and identifying adverse effects before they become irreversible.
